Opinion
Video
Standard of care for frontline treatment of non-V600E-specific pLGG tumors
Author(s):
The experts in pediatric low-grade gliomas (pLGG) delineate the standard of care for frontline treatment of tumors not harboring the BRAF V600E mutation, outlining current best practices and therapeutic approaches.
EP: 1.Overview of pLGG presentation and categorization
EP: 2.Molecular Characterization of pLGG
EP: 3.Less Common Molecular Alterations in pLGG and Testing Recommendations
Now Viewing
EP: 4.Standard of care for frontline treatment of non-V600E-specific pLGG tumors
EP: 5.Ongoing clinical trials for frontline treatment of non-V600E-specific pLGG tumors
EP: 6.Current Treatment of Patients with NF1 pLGG
EP: 7.Standard of Care Pptions Specific for Frontline Treatment of BRAF V600E-Mutated pLGG
EP: 8.Treatment Considerations for Progressive pLGG
EP: 9.Radiation and Targeted Therapies for Progressive pLGG
EP: 10.The Role of Tovorafenib in Treatment of Progressive pLGG
EP: 11.Clinical Trials to Increase Treatment Options in the Progressive Setting
EP: 12.Clinical scenario 1 - BRAFKIAA-1549 fusion
EP: 13.Alternatives and Considerations for Clinical Scenario 1
EP: 14.Clinical Scenario 2 - BRAFV600E
EP: 15.Potential Adverse Events With Targeted Therapies
EP: 16.Clinical Insights: Looking Forward for pLGG
Briefly describe the standard of care options for frontline treatment of pLGG tumors (non-V600E-specific)
Related Videos
Related Content
